Global Multiple Sclerosis Drugs Market By Type (Immunomodulators, Interferons, Immunosuppressants), Route Of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacy, Online Pharmacy) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023-2032

Report Overview

The Global Multiple Sclerosis Drugs Market size is expected to be worth around USD 41 Billion by 2032 from USD 28.2 Billion in 2022, growing at a CAGR of 3.8% during the forecast period from 2022 to 2032.

A chronic inflammatory immune-mediated disease called multiple sclerosis (MS) damages the nerve cells in the spinal cord and brain by producing neurodegeneration, demyelination, and axonal transection. Some of the most often used treatments include muscle relaxants, antidepressants, oral, injectable, infused medicines, physical therapy, and others.

oral drugs such as Teriflunomide, Cladribine, and Dimethyl fumarate are highly used in the treatment of multiple sclerosis. Intravenous infusion therapies such as Ocrelizumab, Alemtuzumab, and Natalizumab & injectable therapies such as Interferon-Beta and Glatiramer Acetate are administered into the muscle and derive fast results.

*Actual Numbers Might Vary In The Final Report

Key Takeaways

• Global Sales Projection: The multiple sclerosis drugs market sales are expected to reach US$ 41 Billion by 2033.
• Growth Rate: The market is predicted to grow at a CAGR of 3.8% from 2023 to 2032.
• Recent Market Value: The market was worth US$ 28.2 Billion in 2022.
• MS Treatments: Treatments include oral drugs, injectables, antidepressants, muscle relaxants, and infused medicines.
• Key Drug Type: There’s a high demand for the Immunosuppressant segment.
• Main Way of Taking Drugs: By route of administration, the oral segment had the largest market share.
• Primary Sellers: The hospital pharmacy segment holds the largest share in distribution channels globally.
• Regional Shares:
  – In 2022, North America had the highest revenue share of 43.1%.
  – Europe accounted for a 28% revenue share in 2022.
• MS Varieties: Multiple sclerosis has four types – secondary-progressive, primary-progressive, relapsing-remitting, and progressive-relapsing.
• Healthcare Spending: Rising expenditure on healthcare is a major driver for the growth of the multiple sclerosis drugs market.
• Market Challenges: The costly treatment can be a hurdle, as might issues like qualified worker shortages in developing nations.
• Research Activities: An increase in R&D activities is a major push for market growth.
• New Technologies: Investments in new tech for the MS drugs market are on the rise.
• Awareness Efforts: Campaigns raising awareness about multiple sclerosis treatments are leading to an increase in demand for these drugs.

Type Analysis

The Immunosuppressant Market Segmentation Accounted for the Largest Share of Multiple Sclerosis Drugs Market

Based on types, the global multiple sclerosis drugs market is segmented into immunomodulators, interferons, immunosuppressants, and others. among these types, the largest market share was occupied by immunosuppressants. because they help patients with relapsing-remitting multiple sclerosis (RRMS) by weakening the immune system, which in turn suppresses the body’s autoimmune onslaught and prevents relapses.

additionally, it is projected that a rise in product approvals for MS medicines will fuel market expansion on a global scale. currently, the immunosuppressants such as alemtuzumab, ocrelizumab, glatiramer Acetate, dimethyl fumarate, natalizumab, fingolimod, interferon beta preparations, and teriflunomide have been authorized for use exclusively in relapse forms of MS.

Route of Administration Analysis

The Oral Segment Accounted for the Largest Share of the Multiple Sclerosis Drugs Market

Based on the route of administration analysis, the global multiple sclerosis drugs market is segmented into injectable, Oral, and Intravenous. Among these routes of administration segment, the largest market share was occupied by oral. Because the oral mode of delivery boosts therapeutic compliance and fosters patient satisfaction. The market is expected to develop as a result of significant therapeutic advancements in the novel oral medications licensed for the therapeutics of MS.

Regulating bodies have approved Fingolimod, Dimethyl Fumarate, and Teriflunomide as three oral segment medications for the treatment of multiple sclerosis. The mechanisms, efficiency, and safety from these medications, which have produced encouraging findings during phase III clinical trials, are important factors in the global expansion of the industry.

Distribution Channel Analysis

The Hospital Pharmacy Segment Accounted for the Largest Market Share in Multiple Sclerosis Drugs Market

Based on distribution channel analysis, the global multiple sclerosis drugs market is segmented into hospital pharmacies, online Pharmacies, retail Pharmacies, and others. Among these distribution channel segments, the largest share was occupied by hospital pharmacies due to favorable health reimbursement and increased government initiatives to enhance the government hospital pharmacies.

Additionally, with more online portals selling prescription medications around the world, the online pharmacy market is set to grow profitably. Additionally, in response to the COVID-19 outbreak, lockdown limitations were implemented globally to stop the virus’s propagation. As a result, there was a greater demand for medication home delivery, which fueled the segment’s expansion.

Key Market Segments

By Type

• Immunomodulators
• Interferons
• Immunosuppressants
• Other types

Route of Administration

• Oral
• Parenteral
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Other Distribution Channels

Drivers

Increasing Multiple Sclerosis Prevalence Drive the Multiple Sclerosis Drugs Market

The multiple sclerosis drugs market is expanding mostly due to the high disease growing incidence. Multiple sclerosis comes in four different forms such as relapsing-remitting, primary-progressive, secondary-progressive, and progressive-relapsing. During the forecast period, the market dynamics will be impacted by these types of high prevalence growth rates.

Improving Healthcare Infrastructure Investment boosts the Multiple Sclerosis market revenue

The increasing expenditure on healthcare contributes to the development of the market for multiple sclerosis and it is a crucial element in determining its growth rate in the forecast period. The market for multiple sclerosis will also grow as more public and private groups and will launch awareness-raising campaigns with increasing market penetration.

Hence, the multiple sclerosis market will also grow as a result of increasing disposable income and the acceleration of the discovery of novel monoclonal antibodies, immunomodulators, immunosuppressants, and interferons. In addition to this, a growing elderly population and a constantly evolving way of life will accelerate the sclerosis drugs market growth.

Restraints

Difficulties Due to a Shortage of Qualified Workers and a Shortage of Healthcare Systems in Emerging Nations

The expensive nature of treating multiple sclerosis may slow down the expansion of the market in the forecast period. The market for multiple sclerosis will face difficulties due to a shortage of qualified workers and a shortage of healthcare systems in emerging nations. Additionally, a decrease in patient visits brought on by the COVID-19 epidemic and an absence of public awareness may constrain and hamper the market’s growth rate in the forecast period.

Opportunity

A Rise in the Amount of R&D Activity

A rise in the quantity of R&D activities is a major factor driving the market’s expansion in the forecast period. This will present advantageous chances for the expansion of the multiple sclerosis market. In addition to this, a rise in drug releases and clearances will speed up the market’s expansion. During the projected period, increased investments in the creation of cutting-edge technologies and an expansion in the number of new markets will also present market opportunities for multiple sclerosis market expansion.

Regional Analysis

North America Held the Highest Share of the Global Multiple Sclerosis Market

Due to a rise in the need for multiple sclerosis therapeutic items, North America held the highest percentage of the global market for multiple sclerosis therapeutics in 2022. Easy access to multiple sclerosis medications and improved favorable government reimbursement policies for multiple sclerosis therapy are other factors that support the market growth for multiple sclerosis medicines in North America.

Additionally, the industry is growing since major companies like Novartis, Pfizer, and Bayer are present in the area. Additionally, it’s been discovered that multiple sclerosis prevalence is higher in areas farthest from the equator; as a result, multiple sclerosis prevalence in North America is frighteningly high.

Infrastructure Expansion and the High Prevalence of Unmet Demands Are Projected to Promote Growth in the Asia Pacific

The market in Asia Pacific is the most profitable, with many potential areas for future expansion. Infrastructure expansion and the high prevalence of unmet demands are projected to promote growth over the projection period. Prominent players are getting into relationships with regional market medicine makers in an effort to take advantage of this growing potential.

Key Regions

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Market Players Analysis

Market players are subject to intense competition from top market players, particularly those with strong brand recognition and high distribution networks like Novartis, Pfizer Inc., and Bayer.

To stay on top of the market, companies have gained various expansion strategies such as partnerships and product launches such as Tecfidera was released by Biogen Idec.

Market Key Players

• Celgene Corporation
• Abbvie Inc.
• Acorda Therapeutics Inc.
• Actelion Pharmaceuticals (Johnson & Johnson)
• Adamas Pharmaceuticals Inc
• Bayer AG
• Biogen Inc.
• Cipla Inc.
• Eli Lilly and Company
• EMD Serono (Merck KGaA)
• Pfizer Inc.
• Sanofi
• Teva Pharmaceuticals Industries Ltd.
• Novartis AG.
• Bristol-Myers Squibb Company
• Hoffmann-La Roche Ltd.
• Other Key Players

Recent Development

• On June 22, 2022, Biogen and Happify Health announced their partnership to support and brace patients with Multiple Sclerosis on the online platform. Through this partnership, the company hopes to support multiple sclerosis patients’ care and treatment journeys, promote holistic health objectives, offer professional advice, and help build a supportive network.
• On July 25, 2022, The U.S. FDA granted natalizumab, the first biosimilar drug created by Polypharma Biologics, approval. The drug is approved for a number of conditions, including relapse multiple sclerosis and relapse-remit multiple sclerosis. The European Medicines Agency (EMA) has also approved the marketing authorization application (MAA) for this potential biosimilar.

Report Scope